02160 CARDIOFLOW-B
- 1.140
- +0.020+1.79%
CARDIOFLOW-B News
MicroPort CardioFlow Medtech's Medical Device Secures Breakthrough Designation From FDA
MicroPort CardioFlow Medtech (HKG:2160) said the U.S. Food and Drug Administration (FDA) granted the "breakthrough device designation" to the company's mitral valve replacement medical device, accordi
Xintong Medical-B (02160): ALTAVALVE was awarded the title of breakthrough device by the FDA
Xintong Medical-B (02160) issued an announcement. AltaValve's transcatheter mitral valve replacement medical device is close...
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
心通醫療-B：2023年度報告
XinTong Medical-B (02160): Vitaflow Liberty receives CE mark approval
Xintong Medical-B (02160) announced that VitaFlow Liberty, independently developed by the group...
Microport Cardioflow Inks Services Deal With Subsidiary
Microport Cardioflow Medtech (HKG:2160) agreed to provide supporting services to its 51%-owned unit Shanghai MicroPort CardioAdvent for 2021, according to a Monday filing with the Hong Kong bourse. Th
Xintong Medical-B (02160.HK) signs 2024 Shanghai Jiuxin Service Procurement Framework Agreement
Gelonghui, April 15, 丨 Xintong Medical-B (02160.HK) announced that on April 15, 2024, the company (for itself and its subsidiaries, joint ventures and associated companies other than Shanghai Zuxin) entered into a 2024 Shanghai Jiuxin Service Procurement Framework Agreement for the period beginning on the 2024 Shanghai Jiuxin Service Procurement Framework Agreement and ending on December 31, 2025. According to this, Shanghai Zuxin will procure certain services from the company and its subsidiaries, joint ventures and associated companies other than Shanghai Jiuxin.
Xintong Medical-B (02160.HK) granted a total of 14.3238 million share options
Xintong Medical-B (02160.HK) issued an announcement. On April 8, 2024, the company decided to grant share options to eligible participants in accordance with the share plan adopted by the company on June 27, 2023 to subscribe for up to 14.3238 million shares of the company's common shares with a face value of 0.000005 US dollars per share. However, this can only be realized after acceptance by the grantor. The exercise price for which the share options were granted was HK$1.002 per share.
Xintong Medical-B (02160.HK): Revenue of 336 million yuan in 2023 increased by 33.9% year-on-year
Gelonghui, March 27 | Xintong Medical-B (02160.HK) announced that for the year ended December 31, 2023, revenue was approximately RMB 336 million, up 33.9% year on year; gross profit was approximately RMB 230 million, up 41.8% year on year; loss attributable to the company's equity shareholders was approximately RMB 472 million; loss attributable to the company's equity shareholders was approximately RMB 454 million; basic loss per share.
Xintong Medical-B (02160) announced its 2023 annual results. Shareholders should account for losses of 472 million yuan, and losses increased by 3.8%
According to the Zhitong Finance App, Xintong Medical-B (02160) announced the results for the year ended December 31, 2023. The group recorded revenue of 336 million yuan, an increase of 33.9% over the previous year. The company's equity shareholders should have accounted for a loss of 472 million yuan, an increase of 3.8%, and a loss of 0.2 yuan per share. According to the report, the 33.9% increase in revenue was mainly due to the rapid increase in the number of surgeries brought about by the increase in the number of admissions of the Group's TAVI products in China, which increased sales of the Group's TAVI products in China. Meanwhile, in 2023, with the Group's TAVI products being sold overseas
CARDIOFLOW-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Xintong Medical-B (02160.HK) will hold a board meeting on March 27 to approve the annual results
Gelonghui March 15 | Xintong Medical-B (02160.HK) issued an announcement. The company's board of directors meeting will be held on March 27, 2024 to review and approve the Group's annual results and announcements for the year ended December 31, 2023, and consider the proposal to pay a final dividend (if any).
CARDIOFLOW-B: DATE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Changes in Hong Kong stocks | Xintong Medical-B (02160) rose more than 7% and is expected to increase revenue by about 31% to 36% year-on-year last year
Xintong Medical-B (02160) rose more than 7%. As of press release, it rose 7.46% to HK$1.44, with a turnover of HK$3.685,400.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
China Approves MicroPort CardioFlow's Application for Atrial Appendage Closure System; Shares Fall 3%
China's medical products administrator approved the application of MicroPort CardioFlow Medtech's (HKG:2160) AnchorMan left atrial appendage closure system, a Sunday filing said. The system is designe
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
MicroPort CardioFlow Subsidiary to Buy 51% Stake in Medical Device Maker
MicroPort CardioFlow Medtech (HKG:2160) subsidiary Shanghai MicroPort CardioFlow Medtech will purchase a 51% stake in Shanghai MicroPort CardioAdvent, a high-tech medical device company, from two vend
Analysis
Price Target
No Data
